Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis.Enterome is using this expertise to generate a pipeline of clinical and pre-clinical candidates (small molecules and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases.Enterome’s strategy is to develop new pharmaceuticals that deliver significantly improved treatments that benefit patients globally and also generate value for its shareholders.

IMMUNO-ONCOLOGY

Immuno-oncology is today a cornerstone of cancer therapy that aims to:

activate the immune system to enhance and/or create anti-cancer immune responses, and to
overcome the immuno-suppressive mechanisms that cancer cells have developed against the immune system.

Enterome’s cancer immunotherapy solution is based on its unique OncoMimics approach. The Enterome approach permits to overcome a frequent challenge of current Immuno-Oncology therapy of insufficient immune cells activation and expansion.
Enterome’s approach permits to activate specific CD8+ T-cells reactive against self-antigens that leads to a sustained immune response against cancer cells.

OncoMimics are microbiome-derived antigens – short peptides – that have a very high amino acid sequence homology with known and well characterized human tumor antigens.

The Company’s lead immune-oncology candidate, EO2401, enters Phase 1b/2a clinical trials in patients with glioblastoma and in patients with adrenal malignancies in July and October 2020, respectively.

Entereome’s second OncoMimic candidate EO2463 is being prepared as a clinical candidate for B-cell malignancies.

MORE ABOUT

INFLAMMATORY AND METABOLIC DISEASES

Inflammatory and metabolic diseases include many disorders and conditions such as inflammatory bowel diseases, type 2 diabetes or obesity.

Enterome’s solution is based on its unique EndoMimics approach, which can generate the next generation of precision biologics by using the natural reservoir of thousands of safe and tolerized human-like effector proteins/ hormones that are produced by the gut bacteria.

The first EndoMimics candidate to emerge from the platform, EM101, is a human hormone mimetic produced by commensal bacteria. EM101 is currently in pre-clinical development for inflammatory bowel disease (IBD).

MORE ABOUT

Enterome - Model EndoMimics - New Generation Of Oral Bioactives

Details